FDA Approves First NGS-Based Companion Diagnostic for RET Fusion-Positive Non-Small Cell Lung Cancer
Thermo Fisher and Oncocyte to Jointly Develop IVD Test Kits and Companion Diagnostic Tests in Precision Oncology - Industry News - mobile.Labmedica.com
Perspective: Thermo Fisher Aims to Reduce Time-to-Results for Cancer NGS | Precision Medicine Online
Thermo Fisher on X: "1 test. 1 sample. 1 report. Oncomine Dx Target Test. Offer your oncologists rapid, actionable results. https://t.co/tI76Mip9Nh https://t.co/6ZjFxNdmg6" / X
Thermo Fisher's Oncomine Dx Target Test Receives the US FDA's Approval as a CDx for the Treatment of IDH1-Mutated Cholangiocarcinoma
Oncomine™ BCR IGH LR Assay, RNA
Oncomine Focus Assay | Thermo Fisher Scientific - US
Thermo Fisher Scientific Announces FDA Approval of Oncomine Dx Target Test as the First NGS-Based Companion Diagnostic to Aid in Therapy Selection for Patients with RET Mutations/Fusions in Thyroid Cancers | Business
Thermo Fisher Scientific Launches CE-IVD (IVDD) Next-Generation Sequencing Test and Analysis Software to Expand Access to Precision Oncology Biomarker Testing